2 Dividend Stocks to Buy in a Recession
While many economists and investors initially expected 2025 to be…
Sell
35
BIO Quote, Financials, Valuation and Earnings
Last price:
$254.68
Seasonality move
:
10.38%
Day range:
$245.02 - $256.42
52-week range:
$244.00 - $387.99
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.80x
P/B ratio:
1.09x
Volume:
232.7K
Avg. volume:
324.2K
1-year change:
-23.45%
Market cap:
$7.1B
Revenue:
$2.6B
EPS (TTM):
-$65.04
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$679.8M | $2.88 | -6.14% | -86.38% | $372.83 |
|
A
Agilent Technologies
|
$1.7B | $1.27 | 3.53% | 20.86% | $151.56 |
|
AVTR
Avantor
|
$1.7B | $0.26 | -4.32% | 159.99% | $24.64 |
|
BRKR
Bruker
|
$965.6M | $0.74 | 5.84% | 28.06% | $68.42 |
|
RMD
ResMed
|
$1.3B | $2.31 | 7.21% | 15.65% | $269.38 |
|
RVTY
Revvity
|
$730.1M | $1.38 | 1.93% | 354.64% | $141.10 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$254.45 | $372.83 | $7.1B | -- | $0.00 | 0% | 2.80x |
|
A
Agilent Technologies
|
$121.18 | $151.56 | $34.5B | 27.86x | $0.25 | 0.79% | 5.36x |
|
AVTR
Avantor
|
$16.30 | $24.64 | $11.1B | 15.67x | $0.00 | 0% | 1.64x |
|
BRKR
Bruker
|
$45.96 | $68.42 | $7B | 60.47x | $0.05 | 0.44% | 2.04x |
|
RMD
ResMed
|
$224.16 | $269.38 | $32.9B | 26.47x | $0.53 | 0.92% | 6.71x |
|
RVTY
Revvity
|
$111.91 | $141.10 | $13.5B | 50.64x | $0.07 | 0.25% | 4.99x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
15.46% | 1.972 | 13.06% | 4.53x |
|
A
Agilent Technologies
|
35.82% | 1.472 | 7.78% | 1.50x |
|
AVTR
Avantor
|
40.51% | 0.803 | 28.27% | 0.65x |
|
BRKR
Bruker
|
54.04% | 1.433 | 23.46% | 0.69x |
|
RMD
ResMed
|
11.35% | 0.169 | 2% | 1.74x |
|
RVTY
Revvity
|
29.13% | 0.855 | 23.4% | 2.75x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
BIO
Bio-Rad Laboratories
|
$341.9M | $58.3M | -20.67% | -23.87% | -134.35% | $81.2M |
|
A
Agilent Technologies
|
$899M | $376M | 13.98% | 20.82% | 23.5% | $334M |
|
AVTR
Avantor
|
$562.9M | $191.5M | 6.78% | 12.92% | 37.3% | $145.8M |
|
BRKR
Bruker
|
$493.3M | $157M | 3.22% | 6.78% | 7.32% | $153.3M |
|
RMD
ResMed
|
$751.3M | $417.2M | 21.74% | 25.56% | 32.54% | $285.2M |
|
RVTY
Revvity
|
$412.3M | $124.5M | 2.37% | 3.45% | 16.09% | $149.8M |
Bio-Rad Laboratories vs. Competitors
-
Which has Higher Returns BIO or A?
Agilent Technologies has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 18.92%. Bio-Rad Laboratories's return on equity of -23.87% beat Agilent Technologies's return on equity of 20.82%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AAgilent Technologies53.48% $1.11 $9.4B -
What do Analysts Say About BIO or A?
Bio-Rad Laboratories has a consensus price target of $372.83, signalling upside risk potential of 46.53%. On the other hand Agilent Technologies has an analysts' consensus of $151.56 which suggests that it could grow by 25.43%. Given that Bio-Rad Laboratories has higher upside potential than Agilent Technologies, analysts believe Bio-Rad Laboratories is more attractive than Agilent Technologies.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories2 2 0 AAgilent Technologies6 10 0 -
Is BIO or A More Risky?
Bio-Rad Laboratories has a beta of 0.984, which suggesting that the stock is 1.622% less volatile than S&P 500. In comparison Agilent Technologies has a beta of 1.108, suggesting its more volatile than the S&P 500 by 10.779%.
-
Which is a Better Dividend Stock BIO or A?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Agilent Technologies offers a yield of 0.79% to investors and pays a quarterly dividend of $0.25 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Agilent Technologies pays out 21.26% of its earnings as a dividend. Agilent Technologies's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or A?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Agilent Technologies quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Agilent Technologies's net income of $318M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Agilent Technologies's PE ratio is 27.86x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.80x versus 5.36x for Agilent Technologies. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.80x -- $667.5M -$715.8M AAgilent Technologies5.36x 27.86x $1.7B $318M
-
Which has Higher Returns BIO or AVTR?
Avantor has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 29.67%. Bio-Rad Laboratories's return on equity of -23.87% beat Avantor's return on equity of 12.92%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B AVTRAvantor33.38% $0.73 $10B -
What do Analysts Say About BIO or AVTR?
Bio-Rad Laboratories has a consensus price target of $372.83, signalling upside risk potential of 46.53%. On the other hand Avantor has an analysts' consensus of $24.64 which suggests that it could grow by 51.15%. Given that Avantor has higher upside potential than Bio-Rad Laboratories, analysts believe Avantor is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories2 2 0 AVTRAvantor8 7 0 -
Is BIO or AVTR More Risky?
Bio-Rad Laboratories has a beta of 0.984, which suggesting that the stock is 1.622% less volatile than S&P 500. In comparison Avantor has a beta of 1.299, suggesting its more volatile than the S&P 500 by 29.904%.
-
Which is a Better Dividend Stock BIO or AVTR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Avantor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Avantor pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios BIO or AVTR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Avantor quarterly revenues of $1.7B. Bio-Rad Laboratories's net income of -$715.8M is lower than Avantor's net income of $500.4M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Avantor's PE ratio is 15.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.80x versus 1.64x for Avantor. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.80x -- $667.5M -$715.8M AVTRAvantor1.64x 15.67x $1.7B $500.4M
-
Which has Higher Returns BIO or BRKR?
Bruker has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 1.4%. Bio-Rad Laboratories's return on equity of -23.87% beat Bruker's return on equity of 6.78%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B BRKRBruker50.36% $0.09 $3.9B -
What do Analysts Say About BIO or BRKR?
Bio-Rad Laboratories has a consensus price target of $372.83, signalling upside risk potential of 46.53%. On the other hand Bruker has an analysts' consensus of $68.42 which suggests that it could grow by 48.86%. Given that Bruker has higher upside potential than Bio-Rad Laboratories, analysts believe Bruker is more attractive than Bio-Rad Laboratories.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories2 2 0 BRKRBruker7 5 0 -
Is BIO or BRKR More Risky?
Bio-Rad Laboratories has a beta of 0.984, which suggesting that the stock is 1.622% less volatile than S&P 500. In comparison Bruker has a beta of 1.184, suggesting its more volatile than the S&P 500 by 18.406%.
-
Which is a Better Dividend Stock BIO or BRKR?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bruker offers a yield of 0.44% to investors and pays a quarterly dividend of $0.05 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Bruker pays out 26.7% of its earnings as a dividend. Bruker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or BRKR?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Bruker quarterly revenues of $979.6M. Bio-Rad Laboratories's net income of -$715.8M is lower than Bruker's net income of $13.7M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Bruker's PE ratio is 60.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.80x versus 2.04x for Bruker. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.80x -- $667.5M -$715.8M BRKRBruker2.04x 60.47x $979.6M $13.7M
-
Which has Higher Returns BIO or RMD?
ResMed has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 26.88%. Bio-Rad Laboratories's return on equity of -23.87% beat ResMed's return on equity of 25.56%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RMDResMed58.6% $2.34 $5.9B -
What do Analysts Say About BIO or RMD?
Bio-Rad Laboratories has a consensus price target of $372.83, signalling upside risk potential of 46.53%. On the other hand ResMed has an analysts' consensus of $269.38 which suggests that it could grow by 20.17%. Given that Bio-Rad Laboratories has higher upside potential than ResMed, analysts believe Bio-Rad Laboratories is more attractive than ResMed.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories2 2 0 RMDResMed7 7 1 -
Is BIO or RMD More Risky?
Bio-Rad Laboratories has a beta of 0.984, which suggesting that the stock is 1.622% less volatile than S&P 500. In comparison ResMed has a beta of 0.738, suggesting its less volatile than the S&P 500 by 26.22%.
-
Which is a Better Dividend Stock BIO or RMD?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ResMed offers a yield of 0.92% to investors and pays a quarterly dividend of $0.53 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. ResMed pays out 27.65% of its earnings as a dividend. ResMed's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RMD?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than ResMed quarterly revenues of $1.3B. Bio-Rad Laboratories's net income of -$715.8M is lower than ResMed's net income of $344.6M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while ResMed's PE ratio is 26.47x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.80x versus 6.71x for ResMed. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.80x -- $667.5M -$715.8M RMDResMed6.71x 26.47x $1.3B $344.6M
-
Which has Higher Returns BIO or RVTY?
Revvity has a net margin of -107.24% compared to Bio-Rad Laboratories's net margin of 12.98%. Bio-Rad Laboratories's return on equity of -23.87% beat Revvity's return on equity of 3.45%.
Company Gross Margin Earnings Per Share Invested Capital BIOBio-Rad Laboratories51.23% -$25.57 $7.8B RVTYRevvity56.53% $0.78 $10.8B -
What do Analysts Say About BIO or RVTY?
Bio-Rad Laboratories has a consensus price target of $372.83, signalling upside risk potential of 46.53%. On the other hand Revvity has an analysts' consensus of $141.10 which suggests that it could grow by 26.17%. Given that Bio-Rad Laboratories has higher upside potential than Revvity, analysts believe Bio-Rad Laboratories is more attractive than Revvity.
Company Buy Ratings Hold Ratings Sell Ratings BIOBio-Rad Laboratories2 2 0 RVTYRevvity8 7 0 -
Is BIO or RVTY More Risky?
Bio-Rad Laboratories has a beta of 0.984, which suggesting that the stock is 1.622% less volatile than S&P 500. In comparison Revvity has a beta of 1.064, suggesting its more volatile than the S&P 500 by 6.441%.
-
Which is a Better Dividend Stock BIO or RVTY?
Bio-Rad Laboratories has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revvity offers a yield of 0.25% to investors and pays a quarterly dividend of $0.07 per share. Bio-Rad Laboratories pays -- of its earnings as a dividend. Revvity pays out 12.74% of its earnings as a dividend. Revvity's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios BIO or RVTY?
Bio-Rad Laboratories quarterly revenues are $667.5M, which are smaller than Revvity quarterly revenues of $729.4M. Bio-Rad Laboratories's net income of -$715.8M is lower than Revvity's net income of $94.6M. Notably, Bio-Rad Laboratories's price-to-earnings ratio is -- while Revvity's PE ratio is 50.64x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bio-Rad Laboratories is 2.80x versus 4.99x for Revvity. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income BIOBio-Rad Laboratories2.80x -- $667.5M -$715.8M RVTYRevvity4.99x 50.64x $729.4M $94.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Ford Stock Undervalued Amid the EV Transition?
There is a lot going on in the electric vehicle…
Is Goldman Sachs Stock a Buy Sell or Hold?
When the Federal Reserve started hiking rates in 2022, banks’…
Stock Ideas
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
56
Is NVDA Stock a Buy?
Market Cap: $3T
P/E Ratio: 41x
Buy
51
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Alerts
Buy
59
GRRR alert for Mar 17
Gorilla Technology Group [GRRR] is down 10.01% over the past day.
Sell
49
SMTC alert for Mar 17
Semtech [SMTC] is down 1.98% over the past day.
Buy
62
PLPC alert for Mar 17
Preformed Line Products [PLPC] is up 1.62% over the past day.
